Molecular Tumour Profiling for Detection of Biomarkers in Renal Cell Tumours

Junker, Kerstin; Sanjmyatav, Jimsgene; Mueller, Joerg P.; Steiner, Thomas; Wunderlich, Heiko; Chyhrai, Aliaksei; Pilchowski, R.; Reichelt, O.; Schubert, Jöerg

doi:10.1016/j.eursup.2007.02.005

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When performing a serum proteome profile that discriminates lung cancer patients from matched controls, the same SAA peak cluster (indicative for N-terminal fragmentation) was found by MALDI-based analysis [86]. Using SELDI-TOF-MS techniques, SAA (11.7 kDa) and transthyretin were identified in a group of proteins specific for RCC, although the value of SAA in monitoring and therapy response needs evaluation in further studies [87–89]. Furthermore, the SELDI-TOF-MS technology was useful to identify SAA as a candidate serum biomarker that strongly correlates with prognosis in neuroblastoma, the most common extra-cranial solid tumour in children [90].…”

Section: Saa and Its Role As A Candidate Tumour-specific Surrogate Bimentioning

confidence: 98%

Serum amyloid A: An acute-phase protein involved in tumour pathogenesis

Malle

Sodin‐Šemrl

Kovacevic

2008

Cell. Mol. Life Sci.

204

181

View full text Add to dashboard Cite

The synthesis of acute-phase protein serum amyloid A (SAA) is largely regulated by inflammation- associated cytokines and a high concentration of circulating SAA may represent an ideal marker for acute and chronic inflammatory diseases. However, SAA is also synthesized in extrahepatic tissues, e.g. human carcinoma metastases and cancer cell lines. An increasing body of in vitro data supports the concept of involvement of SAA in carcinogenesis and neoplastic diseases. Accumulating evidence suggests that SAA might be included in a group of biomarkers to detect a pattern of physiological events that reflect the growth of malignancy and host response. This review is meant to provide a broad overview of the many ways that SAA could contribute to tumour development, and accelerate tumour progression and metastasis, and to gain a better understanding of this acute-phase reactant as a possible link between chronic inflammation and neoplasia.

show abstract

Section: Saa and Its Role As A Candidate Tumour-specific Surrogate Bimentioning

confidence: 98%

Serum amyloid A: An acute-phase protein involved in tumour pathogenesis

Malle

Sodin‐Šemrl

Kovacevic

2008

Cell. Mol. Life Sci.

204

181

View full text Add to dashboard Cite

show abstract

Laparoscopic Partial Nephrectomy

Kenney¹,

Gould²,

Tsai³

et al. 2010

New Technologies in Urology

View full text Add to dashboard Cite

Nierenzellkarzinom 2008

Hammerschmied

Walter²,

Hartmann³

2008

Pathologe

View full text Add to dashboard Cite

By integrating genetic data into the traditional histology and immunohistochemistry-based classification system the revised WHO-classification of malignant tumours (2004) defined additional renal cell carcinoma subtypes, thereby enabling the application of additional diagnostic procedures. Therapy for advanced clear cell renal cell carcinoma has also seen significant progress. This report focuses on these developments, pinpoints current obstacles and provides future prospects.

show abstract

Molecular Tumour Profiling for Detection of Biomarkers in Renal Cell Tumours

Cited by 4 publications

References 9 publications

Serum amyloid A: An acute-phase protein involved in tumour pathogenesis

Serum amyloid A: An acute-phase protein involved in tumour pathogenesis

Laparoscopic Partial Nephrectomy

Nierenzellkarzinom 2008

Contact Info

Product

Resources

About